Beneficial effects resulting from oral administration of Escherichia coli Nissle 1917 on a chronic colitis model
äºBeneficial MicrobesSearch for other papers by E.L.S. Souza in
Current site
Google Scholar
Search for other papers by C.L.V. Campos in
Current site
Google Scholar
Search for other papers by D.C. Reis in
Current site
Google Scholar
Search for other papers by G.D. Cassali in
Current site
Google Scholar
Search for other papers by S.V. Generoso in
Current site
Google Scholar
Search for other papers by V.N. Cardoso in
Current site
Google Scholar
Search for other papers by V. Azevedo in
Current site
Google Scholar
Search for other papers by J.D. Medeiros in
Current site
Google Scholar
Search for other papers by G.R. Fernandes in
Current site
Google Scholar
Search for other papers by J.R. Nicoli in
Current site
Google Scholar
Search for other papers by F.S. Martins in
Current site
Google Scholar
Inflammatory bowel diseases (IBD) are chronic processes involving a deregulated immune response against intestinal microbiota in genetically susceptible individuals. Ulcerative colitis (UC) is an IBD restricted to colonic mucosa and its chronicity is a predisposing factor for colorectal cancer (CRC). Probiotics have been investigated as an adjuvant treatment for UC, and Escherichia coli Nissle 1917 (EcN) was the focus of our investigation. The aim of this study was to investigate the preventive effect of the EcN probiotic in an experimental model of chronic colitis in germ-free (GF) and conventional (CV) mice. CV female mice were used for clinical, immunological and permeability experiments. GF mice were used for a faecal microbiota transplantation assay. To induce colitis, three cycles of 3.0% dextran sulphate sodium (DSS) were administered to the animals. For probiotic treatment, the mice received a daily intragastric gavage of 9.0 log10 cfu of EcN, beginning 10 days before colitis induction and continuing until the end of the experiment. EcN presented beneficial effects when administered preventively. Daily Disease Activity Index (DAI) evolution demonstrated significant difference in remission periods after the first two DSS cycles and during the third one. Reduction in bacterial translocation after probiotic treatment indicated protection of the intestinal barrier. Associated with mucosal preservation, restoration of secretory immunoglobulin A levels and reduction of interleukin (IL)-5, IL-13, tumour necrosis factor and interferon-γ levels were observed in EcN treatment. Finally, when microbiota modification was verified, 16S rRNA-based compositional analysis showed variation of intestinal microbiota between the control and colitis groups. After faecal transplantation using GF mice, it was observed that EcN treatment in CV mice might result in modulated intestinal microbiota. This was observed indirectly in the reduced daily DAI, when colitis was compared with treated group. In conclusion, EcN presented beneficial effects in this model, suggesting its usefulness for treating UC.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
Albert, E., Walker, J., Thiesen, A., Churchill, T. and Madsen K., 2010. Cis-urocanic acid attenuates acute dextran sodium sulphate-induced intestinal inflammation. PLoS ONE 5: e13676. https://doi.org/10.1371/journal.pone.0013676
-
Bell, C.J., Gall, D.G. and Wallace, J.L., 1995. Disruption of colonic electrolyte transport in experimental colitis. American Journal of Physiology 268: 622-630. https://doi.org/10.1152/ajpgi.1995.268.4.G622
-
Blumberg, R.S., 2009. Inflammatory bowel disease: immunologic considerations. In: Greenberger, N.J., Blumberg, R.S. and Burakoff, R. (eds.) Current diagnosis and treatment in gastroenterology, hepatology and endoscopy. McGraw Hill LLC., New York, NY, USA, pp. 11-21.
'Inflammatory bowel disease: immunologic considerations ', () 11 -21.
-
Bolger, A.M., Lohse, M. and Usadel, B., 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30: 2114-2120. https://doi.org/10.1093/bioinformatics/btu170
-
Burisch, J. and Munkholm, P., 2013. Inflammatory bowel disease epidemiology. Current Opinion in Gastroenterology 29: 357-362. https://doi:10.1097/MOG.0b013e32836229fb
-
Caporaso, J.G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F.D., Costello, E.K., Fierer, N., Peña, A.G., Goodrich, J.K., Gordon, J.I., Huttley, G.A., Kelley, S.T., Knights, D., Koenig, J.E., Ley, R.E., Lozupone, C.A., McDonald, D., Muegge, B.D., Pirrung, M., Reeder, J., Sevinsky, J.R., Turnbaugh, P.J., Walters, W.A., Widmann, J., Yatsunenko, T., Zaneveld, J. and Knight, R., 2010. QIIME allows analysis of high-throughput community sequencing data. Nature Methods 7: 335-336. https://doi.org/10.1038/nmeth.f.303
-
Caporaso, J.G., Lauber, C.L., Walters, W.A., Berg-Lyons, D., Lozupone, C.A., Turnbaugh, P.J., Fierer, N. and Knight, R., 2011. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proceedings of the National Academy of Sciences of the USA 108, Suppl. 1: 4516-4522. https://doi.org/10.1073/pnas.1000080107
-
Cooper, H.S., Murthy, S.N., Shah, R.S. and Sedergran, D.J., 1993. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Laboratory Investigation 69: 238-249.
'Clinicopathologic study of dextran sulfate sodium experimental murine colitis ' () 69 Laboratory Investigation : 238 -249.
-
Danino, T., Prindle, A., Kwong, G.A., Skalak, M., Li, H., Allen, K., Hasty, J. and Bhatia, S.N., 2015. Programmable probiotics for detection of cancer in urine. Science Translational Medicine 7: 289ra84. https://doi.org/10.1126/scitranslmed.aaa3519
-
DâAntongiovanni, V., Pellegrini, C., Fornai, M., Colucci, R., Blandizzi, C., Antonioli, L. and Bernardini, N., 2020. Intestinal epithelial barrier and neuromuscular compartment in health and disease. World Journal of Gastroenterology 26: 1564-1579. https://doi.org/10.3748/wjg.v26.i14.1564
-
Das, K.M. and Bajpai, M., 2008. Tropomyosins in human diseases: ulcerative colitis. In: Gunning, P. (eds.) Tropomyosin â advances in experimental medicine and biology. Springer, New York, NY, USA, pp. 158-167. https://doi.org/10.1007/978-0-387-85766-4_13
-
DeSantis, T.Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E.L., Keller, K., Huber, T., Dalevi, D., Hu, P. and Andersen, G.L., 2006. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Applied and Environmental Microbiology 72: 5069-5072. https://doi.org/10.1128/AEM.03006-05
-
Flynn, S. and Eisenstein, S., 2019. Inflammatory bowel disease presentation and diagnosis. Surgical Clinics of North America 99: 1051-1062. https://doi.org/10.1016/j.suc.2019.08.001
-
Food and Agriculture Organisation / World Health Organisation (FAO/WHO), 2002. Guidelines for the evaluation of probiotics in food. FAO/WHO Working Group, London, Ontario, Canada.
-
Generoso, S.V., Viana, M.L., Santos, R.G., Arantes, R.M., Martins, F.S., Nicoli, J.R., Machado, J.A., Correia, M.I. and Cardoso, V.N., 2011. Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii. European Journal of Nutrition 50: 261-269. https://doi.org/10.1007/s00394-010-0134-7
-
Grivennikov, S.I., 2013. Inflammation and colorectal cancer: colitis-associated neoplasia. Seminars in Immunopathology 35: 229-244. https://doi.org/10.1007/s00281-012-0352-6.
-
Guo, X.Y., Liu, X.J. and Hao, J.Y., 2020. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment. Journal of Digestive Diseases 21: 147-159. https://doi.org/10.1111/1751-2980.12849
-
Hou, G. and Bishu, S., 2020. Th17 cells in inflammatory bowel disease: an update for the clinician. Inflammatory Bowel Diseases 26: 653-661. https://doi.org/10.1093/ibd/izz316
-
Hoving, J.C., 2018. Targeting IL-13 as a host-direct therapy against ulcerative colitis. Frontiers in Cell Infection Microbiology 8: 395. https://doi.org/10.3389/fcimb.2018.00395
-
Khoruts, A. and Sadowsky, M.J., 2016. Understanding the mechanisms of faecal microbiota transplantation. Nature Reviews Gastroenterology and Hepatology 13: 508-516. https://doi.org/10.1038/nrgastro.2016.98
-
Koboziev, I., Reinoso, W.C., Furr, K.L. and Grisham, M.B., 2014. Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Radical Biology and Medicine 68: 122-33. https://doi.org/10.1016/j.freeradbiomed.2013.11.008
-
Kruis, W., Fric, P., Pokrotnieks, J., Lukás, M., Fixa, B., Kascák, M., Kamm, M.A., Weismueller, J., Beglinger, C., Stolte, M., Wolff, C. and Schulze, J., 2004. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617-1623. https://doi.org/10.1136/gut.2003.037747
-
Logan, I. and Bowlus, C.L., 2010. The geoepidemiology of autoimmune intestinal diseases. Autoimmunity Reviews 9: 372-378. https://doi.org/10.1016/j.autrev.2009.11.008
-
Love, M.I., Huber, W. and Anders, S., 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology 15: 550. https://doi.org/10.1186/s13059-014-0550-8
-
MagoÄ, T. and Salzberg, S.L., 2011. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 27: 2957-2963. https://doi.org/10.1093/bioinformatics/btr507
-
Marafini, I., Sedda, S., Dinallo, V. and Monteleone, G., 2019. Inflammatory cytokines: from discoveries to therapies in IBD. Expert Opinion on Biological Therapy 19: 1207-1217. https://doi.org/10.1080/14712598.2019.1652267
-
Martins, F.S., Elian, S.D., Vieira, A.T., Tiago, F.C., Martins, A.K., Silva, F.C., Souza, E.L., Sousa, L.P., Araújo, H.R., Pimenta, P.F., Bonjardim, C.A., Arantes, R.M., Teixeira, M.M. and Nicoli, J.R., 2011. Oral treatment with Saccharomyces cerevisiae strain UFMG 905 modulates immune responses and interferes with signal pathways involved in the activation of inflammation in a murine model of typhoid fever. International Journal of Medical Microbiology 301: 359-364. https://doi.org/10.1016/j.ijmm.2010.11.002
-
Martins, F.S., Vieira, A.T., Elian, S.D., Arantes, R.M., Tiago, F.C., Sousa, L.P., Araújo, H.R., Pimenta, P.F., Bonjardim, C.A., Nicoli, J.R. and Teixeira, M.M., 2013. Inhibition of tissue inflammation and bacterial translocation as one of the protective mechanisms of Saccharomyces boulardii against Salmonella infection in mice. Microbes and Infection 15: 270-279. https://doi.org/10.1016/j.micinf.2012.12.007
-
Neurath, M.F., 2014. Cytokines in inflammatory bowel disease. Nature Reviews Immunology 14: 329-342. https://doi.org/10.1038/nri3661
-
OâFlaherty, S., Saulnier, D.M., Pot, B. and Versalovic, J., 2010. How can probiotics and prebiotics impact mucosal immunity? Gut Microbes 1: 293-300. https://doi.org/10.4161/gmic.1.5.12924
-
Ordás, I., Eckmann, L., Talamini, M., Baumgart, D.C. and Sandborn, W.J., 2012. Ulcerative colitis. The Lancet 380: 1606-1619. https://doi.org/10.1016/S0140-6736(12)60150-0
-
Pabst, O., 2012. New concepts in the generation and functions of IgA. Nature Reviews Immunology 12: 821-832. https://doi.org/10.1038/nri3322
-
Pouillon, L., Travis, S., Bossuyt, P., Danese, S. and Peyrin-Biroulet, L., 2020. Head-to-head trials in inflammatory bowel disease: past, present and future. Nature Reviews Gastroenterology and Hepatology 17: 365-376. https://doi.org/10.1038/s41575-020-0293-9
-
Raphael, I., Nalawade, S., Eagar, T.N. and Forsthuber, T.G., 2015. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 74: 5-17. https://doi.org/10.1016/j.cyto.2014.09.011
-
Rogler, G., 2011. Prebiotics and probiotics in ulcerative colitis: where do we stand? Digestion 84: 126-127. https://doi.org/10.1159/000326847
-
Rognes, T., Flouri, T., Nichols, B., Quince, C. and Mahé, F., 2016. VSEARCH: a versatile open source tool for metagenomics. PeerJ 4: e2584. https://doi.org/10.7717/peerj.2584
-
Scaldaferri, F., Gerardi, V., Mangiola, F., Lopetuso, L.R., Pizzoferrato, M., Petito, V., Papa, A., Stojanovic, J., Poscia, A., Cammarota, G. and Gasbarrini, A., 2016. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update. World Journal of Gastroenterology 22: 5505-5511. https://doi.org/10.3748/wjg.v22.i24.5505
-
Schierack, P., Kleta, S., Tedin, K., Babila, J.T., Oswald, S., Oelschlaeger, T.A., Hiemann, R., Paetzold, S. and Wieler, L.H., 2011. E. coli Nissle 1917 affects Salmonella adhesion to porcine intestinal epithelial cells. PLoS ONE 6: e14712. https://doi.org/10.1371/journal.pone.0014712
-
Sommer, F. and Bäckhed, F., 2013. The gut microbiota â masters of host development and physiology. Nature Reviews Microbiology 11: 227-238. https://doi.org/10.1038/nrmicro2974
-
Souza, M.H.L.P., Troncon, L.E.A., Rodrigues, C.M., Viana, C.F.G., Onofre, P.H.C., Monteiro, R.A., Passos, A.D.C., Martinelli, A.L.C. and Meneghelli, U.G., 2002. Trends in the occurrence (1980-1999) and clinical features of Crohnâs disease and ulcerative colitis in a university hospital in southeastern Brazil. Arquivos de Gastroenterologia 39: 98-105. https://doi.org/10.1590/s0004-28032002000200006
-
Triantafillidis, J.K., Merikas, E. and Georgopoulos, F., 2011. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Design, Development and Therapy 5: 185-210. https://doi.org/10.2147/DDDT.S11290
-
Wirtz, S., Neufert, C., Weigmann, B. and Neurath, M.F., 2007. Chemically induced mouse models of intestinal inflammation. Nature Protocols 2: 541-546. https://doi.org/10.1038/nprot.2007.41
-
Yan, Y., Kolachala, V., Dalmasso, G., Nguyen, H., Laroui, H., Sitaraman, S.V. and Merlin, D., 2009. Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS ONE 4: e6073. https://doi.org/10.1371/journal.pone.0006073
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 1200 | 453 | 60 |
| å ¨ææµè§æ¬¡æ° | 19 | 3 | 0 |
| PDFä¸è½½æ¬¡æ° | 19 | 1 | 0 |
Beneficial effects resulting from oral administration of Escherichia coli Nissle 1917 on a chronic colitis model
äºBeneficial MicrobesSearch for other papers by E.L.S. Souza in
Current site
Google Scholar
PubMed
Search for other papers by C.L.V. Campos in
Current site
Google Scholar
PubMed
Search for other papers by D.C. Reis in
Current site
Google Scholar
PubMed
Search for other papers by G.D. Cassali in
Current site
Google Scholar
PubMed
Search for other papers by S.V. Generoso in
Current site
Google Scholar
PubMed
Search for other papers by V.N. Cardoso in
Current site
Google Scholar
PubMed
Search for other papers by V. Azevedo in
Current site
Google Scholar
PubMed
Search for other papers by J.D. Medeiros in
Current site
Google Scholar
PubMed
Search for other papers by G.R. Fernandes in
Current site
Google Scholar
PubMed
Search for other papers by J.R. Nicoli in
Current site
Google Scholar
PubMed
Search for other papers by F.S. Martins in
Current site
Google Scholar
PubMed
Inflammatory bowel diseases (IBD) are chronic processes involving a deregulated immune response against intestinal microbiota in genetically susceptible individuals. Ulcerative colitis (UC) is an IBD restricted to colonic mucosa and its chronicity is a predisposing factor for colorectal cancer (CRC). Probiotics have been investigated as an adjuvant treatment for UC, and Escherichia coli Nissle 1917 (EcN) was the focus of our investigation. The aim of this study was to investigate the preventive effect of the EcN probiotic in an experimental model of chronic colitis in germ-free (GF) and conventional (CV) mice. CV female mice were used for clinical, immunological and permeability experiments. GF mice were used for a faecal microbiota transplantation assay. To induce colitis, three cycles of 3.0% dextran sulphate sodium (DSS) were administered to the animals. For probiotic treatment, the mice received a daily intragastric gavage of 9.0 log10 cfu of EcN, beginning 10 days before colitis induction and continuing until the end of the experiment. EcN presented beneficial effects when administered preventively. Daily Disease Activity Index (DAI) evolution demonstrated significant difference in remission periods after the first two DSS cycles and during the third one. Reduction in bacterial translocation after probiotic treatment indicated protection of the intestinal barrier. Associated with mucosal preservation, restoration of secretory immunoglobulin A levels and reduction of interleukin (IL)-5, IL-13, tumour necrosis factor and interferon-γ levels were observed in EcN treatment. Finally, when microbiota modification was verified, 16S rRNA-based compositional analysis showed variation of intestinal microbiota between the control and colitis groups. After faecal transplantation using GF mice, it was observed that EcN treatment in CV mice might result in modulated intestinal microbiota. This was observed indirectly in the reduced daily DAI, when colitis was compared with treated group. In conclusion, EcN presented beneficial effects in this model, suggesting its usefulness for treating UC.
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 1200 | 453 | 60 |
| å ¨ææµè§æ¬¡æ° | 19 | 3 | 0 |
| PDFä¸è½½æ¬¡æ° | 19 | 1 | 0 |
